- Home
- All Stock List
- NSE
- Solara Active Pharma Sciences Ltd Share Price
Solara Active Pharma Sciences Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap
-
6
Like
-
Share
-
Feedback
518.60
-57.00 (-9.90%)
-
Underperforms Index
6.31%
Return (1Y)
Underperformed Nifty 50 by 6.58%
-
More Volatile
3.17%
Standard Deviation (1Y)
Higher than Nifty 50 by 2.19%
-
Consistent Performer
8/12
Months
beaten Nifty 50
-
AxisDirect View
No View
883
367
News & Announcements
-
Solara Active Pharma Sciences reports consolidated net loss of Rs 2.10 crore in the March 2025 quarter
15 - May - 2025 12:00 | 1 day ago
Net Loss of Solara Active Pharma Sciences reported to Rs 2.10 crore in the quarter ended March 2025 as against net loss of Rs 255.34 crore during the previous quarter ended March 2024. Sales declined 8.82% to Rs 273.01 crore in the quarter ended March 2025 as against Rs 299.43 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 0.54 crore in the year ended March 2025 as against net loss of Rs 567.39 crore during the previous year ended March 2024. Sales declined 0.40% to Rs 1283.76 crore in the year ended March 2025 as against Rs 1288.92 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 273.01 299.43 -9 1283.76 1288.92 0 OPM % 16.62 3.26 - 16.07 -7.38 - PBDT 22.20 -19.23 LP 99.79 -194.92 LP PBT -2.10 -44.48 95 0.54 -298.25 LP NP -2.10 -255.34 99 0.54 -567.39 LP Powered by Capital Market - Live News
-
Solara Active Pharma?s Ambernath facility clears USFDA inspection
12 - May - 2025 12:00 | 4 days ago
The Agency with their designated investigator inspected the facility from 5th to 9th May 2025.
The inspection established that the site is in an ?Acceptable State of Compliance? with Zero Form 483 inspectional observations from US FDA.
Commenting on the inspection outcome, Sandeep Rao, MD & CEO said, ?We are very happy with the successful inspection outcome of our Ambernath API site with Zero 483 inspectional observations. This is the third (3rd) consecutive successful inspection outcome, with Zero 483 inspectional observations, across the Solara network of manufacturing facilities. The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy.?
Solara Active Pharma Sciences is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, the company offers a basket of diversified, high-value commercial APIs and contract manufacturing services.
The company reported consolidated net profit of Rs 8.09 crore in Q3 FY25 as compared with net loss of Rs 275.34 crore in Q3 FY24. Net sales increased 41.7% YoY to Rs 300.31 crore in Q3 FY25.
The scrip rose 0.54% to end at Rs 502.80 on the BSE.
Powered by Capital Market - Live News
-
-
Solara Active Pharma?s Ambernath facility clears USFDA inspection
12 - May - 2025 12:00 | 4 days ago
The Agency with their designated investigator inspected the facility from 5th to 9th May 2025.
The inspection established that the site is in an ?Acceptable State of Compliance? with Zero Form 483 inspectional observations from US FDA.
Commenting on the inspection outcome, Sandeep Rao, MD & CEO said, ?We are very happy with the successful inspection outcome of our Ambernath API site with Zero 483 inspectional observations. This is the third (3rd) consecutive successful inspection outcome, with Zero 483 inspectional observations, across the Solara network of manufacturing facilities. The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy.?
Solara Active Pharma Sciences is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, the company offers a basket of diversified, high-value commercial APIs and contract manufacturing services.
The company reported consolidated net profit of Rs 8.09 crore in Q3 FY25 as compared with net loss of Rs 275.34 crore in Q3 FY24. Net sales increased 41.7% YoY to Rs 300.31 crore in Q3 FY25.
The scrip rose 0.54% to end at Rs 502.80 on the BSE.
Powered by Capital Market - Live News
-
-
-
Solara Active Pharma Sciences reports consolidated net loss of Rs 2.10 crore in the March 2025 quarter
15 - May - 2025 12:00 | 1 day ago
Net Loss of Solara Active Pharma Sciences reported to Rs 2.10 crore in the quarter ended March 2025 as against net loss of Rs 255.34 crore during the previous quarter ended March 2024. Sales declined 8.82% to Rs 273.01 crore in the quarter ended March 2025 as against Rs 299.43 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 0.54 crore in the year ended March 2025 as against net loss of Rs 567.39 crore during the previous year ended March 2024. Sales declined 0.40% to Rs 1283.76 crore in the year ended March 2025 as against Rs 1288.92 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 273.01 299.43 -9 1283.76 1288.92 0 OPM % 16.62 3.26 - 16.07 -7.38 - PBDT 22.20 -19.23 LP 99.79 -194.92 LP PBT -2.10 -44.48 95 0.54 -298.25 LP NP -2.10 -255.34 99 0.54 -567.39 LP Powered by Capital Market - Live News
-
Solara Active Pharma?s Ambernath facility clears USFDA inspection
12 - May - 2025 12:00 | 4 days ago
The Agency with their designated investigator inspected the facility from 5th to 9th May 2025.
The inspection established that the site is in an ?Acceptable State of Compliance? with Zero Form 483 inspectional observations from US FDA.
Commenting on the inspection outcome, Sandeep Rao, MD & CEO said, ?We are very happy with the successful inspection outcome of our Ambernath API site with Zero 483 inspectional observations. This is the third (3rd) consecutive successful inspection outcome, with Zero 483 inspectional observations, across the Solara network of manufacturing facilities. The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy.?
Solara Active Pharma Sciences is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, the company offers a basket of diversified, high-value commercial APIs and contract manufacturing services.
The company reported consolidated net profit of Rs 8.09 crore in Q3 FY25 as compared with net loss of Rs 275.34 crore in Q3 FY24. Net sales increased 41.7% YoY to Rs 300.31 crore in Q3 FY25.
The scrip rose 0.54% to end at Rs 502.80 on the BSE.
Powered by Capital Market - Live News
-
-
-
Solara Active Pharma Sciences reports consolidated net loss of Rs 2.10 crore in the March 2025 quarter
15 - May - 2025 12:00 | 1 day ago
Net Loss of Solara Active Pharma Sciences reported to Rs 2.10 crore in the quarter ended March 2025 as against net loss of Rs 255.34 crore during the previous quarter ended March 2024. Sales declined 8.82% to Rs 273.01 crore in the quarter ended March 2025 as against Rs 299.43 crore during the previous quarter ended March 2024.
For the full year,net profit reported to Rs 0.54 crore in the year ended March 2025 as against net loss of Rs 567.39 crore during the previous year ended March 2024. Sales declined 0.40% to Rs 1283.76 crore in the year ended March 2025 as against Rs 1288.92 crore during the previous year ended March 2024.
Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 273.01 299.43 -9 1283.76 1288.92 0 OPM % 16.62 3.26 - 16.07 -7.38 - PBDT 22.20 -19.23 LP 99.79 -194.92 LP PBT -2.10 -44.48 95 0.54 -298.25 LP NP -2.10 -255.34 99 0.54 -567.39 LP Powered by Capital Market - Live News
-
Solara Active Pharma?s Ambernath facility clears USFDA inspection
12 - May - 2025 12:00 | 4 days ago
The Agency with their designated investigator inspected the facility from 5th to 9th May 2025.
The inspection established that the site is in an ?Acceptable State of Compliance? with Zero Form 483 inspectional observations from US FDA.
Commenting on the inspection outcome, Sandeep Rao, MD & CEO said, ?We are very happy with the successful inspection outcome of our Ambernath API site with Zero 483 inspectional observations. This is the third (3rd) consecutive successful inspection outcome, with Zero 483 inspectional observations, across the Solara network of manufacturing facilities. The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy.?
Solara Active Pharma Sciences is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, the company offers a basket of diversified, high-value commercial APIs and contract manufacturing services.
The company reported consolidated net profit of Rs 8.09 crore in Q3 FY25 as compared with net loss of Rs 275.34 crore in Q3 FY24. Net sales increased 41.7% YoY to Rs 300.31 crore in Q3 FY25.
The scrip rose 0.54% to end at Rs 502.80 on the BSE.
Powered by Capital Market - Live News
-
-
Solara Active Pharma?s Ambernath facility clears USFDA inspection
12 - May - 2025 12:00 | 4 days ago
The Agency with their designated investigator inspected the facility from 5th to 9th May 2025.
The inspection established that the site is in an ?Acceptable State of Compliance? with Zero Form 483 inspectional observations from US FDA.
Commenting on the inspection outcome, Sandeep Rao, MD & CEO said, ?We are very happy with the successful inspection outcome of our Ambernath API site with Zero 483 inspectional observations. This is the third (3rd) consecutive successful inspection outcome, with Zero 483 inspectional observations, across the Solara network of manufacturing facilities. The inspection outcome demonstrates our commitment to regulatory excellence at our global manufacturing sites and relentless focus on world-class quality and compliance, which remains a key pillar of our growth strategy.?
Solara Active Pharma Sciences is a pure play global API manufacturer supported by state-of-the-art R&D and manufacturing facilities. With 6 manufacturing facilities and an R&D Centre, the company offers a basket of diversified, high-value commercial APIs and contract manufacturing services.
The company reported consolidated net profit of Rs 8.09 crore in Q3 FY25 as compared with net loss of Rs 275.34 crore in Q3 FY24. Net sales increased 41.7% YoY to Rs 300.31 crore in Q3 FY25.
The scrip rose 0.54% to end at Rs 502.80 on the BSE.
Powered by Capital Market - Live News
-
-
Stock Trivia
FII shareholding in Solara Active Pharma Sciences Ltd has decreased by -7.42% since past 1 Year
GovT shareholding in Solara Active Pharma Sciences Ltd has decreased by -26.32% since past 1 Year
FII shareholding in Solara Active Pharma Sciences Ltd has decreased by -7.42% since past 1 Year
MF shareholding in Solara Active Pharma Sciences Ltd has decreased by -24.98% since past 1 Year
Promoter shareholding in Solara Active Pharma Sciences Ltd has increased by 24.45% since past 1 Year
GovT shareholding in Solara Active Pharma Sciences Ltd has decreased by -26.32% since past 1 Year
FII shareholding in Solara Active Pharma Sciences Ltd has decreased by -7.42% since past 1 Year
GovT shareholding in Solara Active Pharma Sciences Ltd has decreased by -26.32% since past 1 Year
